Evidence map›Paper›PMID 36324741›Full record

ReviewFrontiers in cardiovascular medicine2022

Stroke prevention during and after transcatheter aortic valve implantation: From cerebral protection devices to antithrombotic management.

Victor Alfonso Jimenez Diaz, Rodrigo Estevez Loureiro, Jose Antonio Baz Alonso, Pablo Juan Salvadores, Guillermo Bastos Fernandez, Berenice Caneiro Queija, Cesar Veiga Garcia, Andres Iñiguez Romo

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Recognition of Strokes in the ICU: A Narrative Review.Journal of cardiovascular development and disease · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Victor Alfonso Jimenez DiazDepartment of Cardiology, Hospital Álvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
Rodrigo Estevez LoureiroDepartment of Cardiology, Hospital Álvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
Jose Antonio Baz AlonsoDepartment of Cardiology, Hospital Álvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
Pablo Juan SalvadoresDepartment of Cardiology, Hospital Álvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
Guillermo Bastos FernandezDepartment of Cardiology, Hospital Álvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
Berenice Caneiro QueijaDepartment of Cardiology, Hospital Álvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.
Cesar Veiga GarciaCardiovascular Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain.
Andres Iñiguez RomoDepartment of Cardiology, Hospital Álvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since its conception, transcatheter aortic valve implantation (TAVI) has undergone important improvements both in the implantation technique and in transcatheter devices, allowing an enthusiastic adoption of this therapeutic approach in a wide population of patients previously without a surgical option and managed conservatively. Nowadays, patients with severe symptomatic aortic stenosis are typically managed with TAVI, regardless of their risk to surgery, improving the prognosis of patients and thus achieving an exponential global expansion of its use. However, thromboembolic and hemorrhagic complications remain a latent concern in TAVI recipients. Both complications can appear simultaneously in the periprocedural period or during the follow-up, and when minor, they resolved without apparent sequelae, but in a relevant percentage of cases, they are devastating, overshadowing the benefit achieved with TAVI. Our review outlines the etiology and incidence of thromboembolic complications associated with TAVI, the main current strategies for their prevention, and the implications of its pharmacological management at the follow-up in a TAVI population, mostly frail and predisposed to bleeding complications.

Indexed as

antithrombotic therapyaortic stenosis (AS)cerebral embolic protection devicescomplicationstroketranscatheter aortic valve implantation (TAVI)

Identifiers

PMID36324741
PMCPMC9618870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.